A Post-Marketing Clinical Trial of Pemafibrate in Patients ｗith Hypercholesterolemia and Inadequate Response to Statins

NCT07634484 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: Pemafibrate 0.2 mg/day
DRUG: Pemafibrate 0.4 mg/day
DRUG: Placebo

Sponsor

Kowa Company, Ltd.